Tracking cross-border transmission of Rwanda’s successful dominant rifampicin-resistant Mycobacterium tuberculosis clone using genomic markers
- Publicada
- Servidor
- medRxiv
- DOI
- 10.64898/2026.03.29.26349652
Background
In Rwanda, genomic surveillance identified a dominant multidrug-resistant tuberculosis (MDR-TB) strain, the R3clone, responsible for approximately 70% of rifampicin-resistant TB cases. Its presence beyond Rwanda remains unexplored.
Methods
Unique genetic signatures of the R3clone were defined using whole-genome sequencing of MDR-TB isolates from Rwanda. We developed a targeted qPCR assay detecting a clone-specific single-nucleotide polymorphism. With these tools, we screened isolates from neighbouring countries and public genomic repositories.
Results
We identified 375 R3clone isolates, including 264 from historical Rwandan collections (1991-2021), 49 from recent Rwandan diagnostic routine (2021-2024), 25 from historical Burundi isolates (2002-2013), and 37 among public repositories from several countries. The R3clone-specific qPCR showed 100% specificity in distinguishing the R3clone from other MTBC (sub-)lineages. Transmission analysis revealed cross-border transmission of the R3clone within the Great Lakes Region.
Conclusion
This study comprehensively assesses cross-border transmission of a dominant MDR-TB strain, highlighting the need for coordinated international surveillance.
Article summary line
Genomic surveillance and targeted molecular diagnostics reveal cross-border transmission of Rwanda’s dominant multidrug-resistant tuberculosis clone throughout the African Great Lakes Region.